Equity Overview
Price & Market Data
Price: $0.595
Daily Change: -$0.004 / 0.67%
Daily Range: $0.59 - $0.63
Market Cap: $19,978,024
Daily Volume: 66,154
Performance Metrics
1 Week: -3.29%
1 Month: -1.70%
3 Months: 75.02%
6 Months: 58.39%
1 Year: -82.24%
YTD: 15.75%
Company Details
Employees: 17
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.